MX2020007222A - Metodos para el tratamiento de afecciones inflamatorias de la piel. - Google Patents

Metodos para el tratamiento de afecciones inflamatorias de la piel.

Info

Publication number
MX2020007222A
MX2020007222A MX2020007222A MX2020007222A MX2020007222A MX 2020007222 A MX2020007222 A MX 2020007222A MX 2020007222 A MX2020007222 A MX 2020007222A MX 2020007222 A MX2020007222 A MX 2020007222A MX 2020007222 A MX2020007222 A MX 2020007222A
Authority
MX
Mexico
Prior art keywords
minocycline
inflammatory skin
skin conditions
treating inflammatory
skin condition
Prior art date
Application number
MX2020007222A
Other languages
English (en)
Spanish (es)
Inventor
Bijay Kumar Padhi
Rajeev Singh Raghuvanshi
Swati Kulkarni
Shavas Alikunju
Srinivas Ramchandra Sidgiddi
Anirudh Gautam
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65269058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020007222(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of MX2020007222A publication Critical patent/MX2020007222A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020007222A 2018-01-07 2019-01-07 Metodos para el tratamiento de afecciones inflamatorias de la piel. MX2020007222A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741023993 2018-01-07
PCT/IB2019/000144 WO2019135166A1 (en) 2018-01-07 2019-01-07 Minocycline for treating inflammatory skin conditions

Publications (1)

Publication Number Publication Date
MX2020007222A true MX2020007222A (es) 2020-12-10

Family

ID=65269058

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007222A MX2020007222A (es) 2018-01-07 2019-01-07 Metodos para el tratamiento de afecciones inflamatorias de la piel.

Country Status (11)

Country Link
US (5) US11191740B2 (cg-RX-API-DMAC7.html)
EP (1) EP3735249A1 (cg-RX-API-DMAC7.html)
JP (3) JP7561029B2 (cg-RX-API-DMAC7.html)
KR (1) KR102705507B1 (cg-RX-API-DMAC7.html)
CN (1) CN111818927A (cg-RX-API-DMAC7.html)
AU (2) AU2019205134B9 (cg-RX-API-DMAC7.html)
BR (1) BR112020013789A2 (cg-RX-API-DMAC7.html)
CA (1) CA3087838A1 (cg-RX-API-DMAC7.html)
EA (1) EA202091653A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020007222A (cg-RX-API-DMAC7.html)
WO (1) WO2019135166A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007222A (es) 2018-01-07 2020-12-10 Dr Reddys Laboratories Ltd Metodos para el tratamiento de afecciones inflamatorias de la piel.
WO2020018859A1 (en) 2018-07-19 2020-01-23 Clark Equipment Company Display position for cab with overhead door
US20260216213A1 (en) * 2024-11-01 2026-07-30 Journey Medical Corporation Methods for treating rosacea
CN120324439A (zh) * 2025-03-05 2025-07-18 福安药业集团宁波天衡制药有限公司 一种稳定的盐酸米诺环素胶囊及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
EP1716856A3 (en) * 2001-04-05 2009-02-18 Collagenex Pharmaceuticals, Inc. The treatment of acne
WO2003088906A2 (en) 2002-04-16 2003-10-30 Collagenex Pharmaceuticals, Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
AU2010302350B2 (en) 2009-10-02 2015-06-18 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US20140186269A1 (en) 2013-01-03 2014-07-03 Foamix Ltd. Vehicle compositions essentially free of pharmaceutically active agents for the improved treatment of acne and related disorders
PT106679B (pt) 2012-11-27 2015-03-25 Hovione Farmaciencia Sa Formulações tópicas de tetraciclinas, sua preparação e usos
MX2020007222A (es) 2018-01-07 2020-12-10 Dr Reddys Laboratories Ltd Metodos para el tratamiento de afecciones inflamatorias de la piel.

Also Published As

Publication number Publication date
RU2020125984A (ru) 2022-02-07
US20210121420A1 (en) 2021-04-29
JP2026031656A (ja) 2026-02-24
US20260191804A1 (en) 2026-07-09
KR102705507B1 (ko) 2024-09-10
AU2019205134B2 (en) 2024-11-07
US20230131030A1 (en) 2023-04-27
RU2020125984A3 (cg-RX-API-DMAC7.html) 2022-02-07
WO2019135166A9 (en) 2020-07-16
US20190209500A1 (en) 2019-07-11
CN111818927A (zh) 2020-10-23
CA3087838A1 (en) 2019-07-11
US10905664B2 (en) 2021-02-02
AU2019205134B9 (en) 2025-02-20
AU2019205134A1 (en) 2020-08-20
KR20200108018A (ko) 2020-09-16
EA202091653A1 (ru) 2020-12-23
JP2021509409A (ja) 2021-03-25
AU2025200826A1 (en) 2025-02-27
JP2024098011A (ja) 2024-07-19
US12594252B2 (en) 2026-04-07
JP7561029B2 (ja) 2024-10-03
WO2019135166A1 (en) 2019-07-11
US20200222345A1 (en) 2020-07-16
US11364212B2 (en) 2022-06-21
AU2019205134A2 (en) 2020-08-20
EP3735249A1 (en) 2020-11-11
US11191740B2 (en) 2021-12-07
BR112020013789A2 (pt) 2021-02-17

Similar Documents

Publication Publication Date Title
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX389927B (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
MX2021004828A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2021000289A (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
MY188139A (en) Sodium channel modulators for the treatment of pain
AR105712A1 (es) Composiciones de insulina de rápida acción
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
EA201592058A1 (ru) Применение ландиолола гидрохлорида в длительном лечении тахиаритмии
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
EA202193276A1 (ru) Способы лечения холангиокарциномы
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX385725B (es) Composición farmacéutica que comprende sumatriptán para tratamiento de migraña.
MX2022001200A (es) Metodo para el tratamiento de accidente cerebrovascular usando un derivado triciclico.
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности